Main Profile

At A Glance

Brian Druker (OHSU) Part 3: Extending the Imatinib Paradigm

Imatinib has become the paradigm of targeted drug development. The lessons learned from the clinical trials of imatinib treatment of chronic myeloid leukemia will be reviewed in this section. This will include examples of where imatinib has or has not worked, analysis of target expression versus activation and a discussion of how the success of imatinib can be translated to other malignancies. The section concludes with what this means for research to control or cure cancer in the coming decades. See more at http://www.ibioseminars.org
Length: 22:10

Contact

Questions about Brian Druker (OHSU) Part 3: Extending the Imatinib Paradigm

Want more info about Brian Druker (OHSU) Part 3: Extending the Imatinib Paradigm? Get free advice from education experts and Noodle community members.

  • Answer

Ask a New Question